Literature DB >> 578848

Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.

J J Sternberg, R B Bracken, P B Handel, D E Johnson.   

Abstract

Twelve patients with metastatic transitional cell carcinoma from the urinary bladder were treated with a combination chemotherapy program consisting of cisplatinum, cyclophosphamide, and doxorubicin hydrochloride (CISCA). Ten patients had conditions for which a response to therapy could be determined, and nine achieved an objective response (one complete response, eight partial responses). Two additional patients with metastatic transitional cell carcinoma from the renal pelvis were also treated, and one achieved a partial response. In our experience, CISCA combination chemotherapy has given the highest response rate of any protocol thus far tested in advanced, metastatic urinary tract carcinoma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 578848

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Three-drug combination chemotherapy for advanced urothelial tract carcinoma.

Authors:  S Ohshima; Y Ono; T Fujita; Y Aso
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).

Authors:  P H Smith; J A Child; J H Mulder; A T Van Oosterom; J A Martinez-Pineiro; B Richards; G Stoter; O Dalesio; M De Pauw; R Sylvester
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Adjuvant chemotherapy for invasive bladder cancer.

Authors:  Y Uekado; T Shinka; A Hirano; T Ohkawa
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Combination chemotherapy for advanced urothelial-tract carcinoma.

Authors:  M Sahashi; Y Ono; O Matsuura; S Ohshima; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 8.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Results of systemic chemotherapy of advanced bladder carcinomas (phase II study).

Authors:  G Stadie; A Möller; H Müller; D Katenkamp; H Urban; D Kob
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

10.  Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor.

Authors:  Y Kondo; M Satoh; N Imura; M Akimoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.